Sartorius Stedim Biotech (SSB) has acquired BioOutsource Ltd in order to expand its service portfolio. The Scottish privately-owned company has been operating in biotechnology since 2007, and turned over about about €9M in the last year.
BioOutsource provides contract testing services to global biopharmaceutical clients in order to monitor the safety and quality of biologic drugs and vaccines. The company has in particular specialized in offering a comprehensive suite of services which support testing of biologic and vaccine products throughout development and manufacture. This acquisition will develop SSB’s service offering throughout the drug development pathway. The contractual parties agreed not to disclose any further transaction details
Gerry MacKay, CEO of BioOutsource, commented: “We are delighted to have found a strong partner with a broad customer base, international reach and a powerful brand. With Sartorius Stedim Biotech we will be able to scale our business to the next level and invest in new adjacent services. As a part of this group, we will have the opportunity to work with more international customers particularly in areas like the United States and Asia where there is significant investment in biosimilar development and manufacturing. We would also like to take this opportunity to thank one of our original shareholders Scottish Investment Bank, the investment arm of Scottish Enterprise, for their continued investment and support over the last 7 years”.
According to Reinhard Vogt, member of SSB’s Board: “By adding contract testing services, we will be able to support our biopharma clients even better in their drive to fast-track their new drug candidates through the development and clinical test phases and facilitate lot release testing in large scale manufacturing. The highly qualified team at BioOutsource will ideally complement our expertise, and we are looking forward to working with them”.